Towards a novel low-cost effective Schistosomiasis vaccine for control
A pilot study to assess the feasibility for the development of a safe and cost-effective vaccine (Sm-TSP-2) against schistosomiasis tailored to the paediatric target population, more than 200 million people in most of the resource-deprived regions of the devloping world. The outcome is an innovatively developed and licensed vaccin by 2025 with an efficacy of 40% to 50%. To achieve this, a worldwide partnership is formed.
Project number
NL-KVK-27378529-LSH14UG07Total budget
€ 135,056Countries
UgandaProject status
FinalisedBudget spent
100.00 % spent
Tied status
UntiedStartdate:
Enddate:
Contact
iati@rvo.nlProject partners
Academisch Medisch Centrum, Albert B. Sabin Vaccine Institute, Inc., Leids Universitair Medisch Centrum (LUMC), Netherlands Enterprise Agency, Q-Biologicals N.V.Sectors
Infectious disease control| Type | Provider | Provider ref. | Receiver | Receiver ref. | Value (€) | Date | Value date |
|---|---|---|---|---|---|---|---|
| Incoming Funds | 135,056.00 | 18-12-2014 | 18-12-2014 | ||||
| Outgoing Commitment | Leids Universitair Medisch Centrum (LUMC) | 135,056.00 | 18-12-2014 | 18-12-2014 | |||
| Disbursement | Leids Universitair Medisch Centrum (LUMC) | 40,517.00 | 05-02-2015 | 05-02-2015 | |||
| Disbursement | Leids Universitair Medisch Centrum (LUMC) | 40,517.00 | 02-04-2015 | 02-04-2015 | |||
| Disbursement | Leids Universitair Medisch Centrum (LUMC) | 40,516.00 | 02-07-2015 | 02-07-2015 | |||
| Disbursement | Leids Universitair Medisch Centrum (LUMC) | 13,506.00 | 10-08-2017 | 10-08-2017 |